Vanda Pharmaceuticals Inc. Common Stock (VNDA)
Stock · NASDAQ · Health Care
$4.03as of 10/16/2026
Price chart
Active signals
VNDA Signal Track Record
How signals performed across all stocks →What VNDA's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 32 | +3.8% | 66% | September 29, 2026 |
| Bollinger Band Breakdown | 23 | +1.9% | 52% | October 2, 2026 |
| Bollinger Band Breakout | 21 | -7.1% | 29% | August 19, 2026 |
| 200-Day Moving Average TouchActive now | 14 | -1.1% | 43% | May 20, 2026 |
| Any 20-session window (baseline) | -1.2% | 46% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About VNDA
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbance…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 533
- Website
- www.vandapharma.com/
Fundamentals
- 1-day range
- $4.28$4.54
- Market cap
- $307.59M
- P/E (trailing)
- —
- P/E (forward)
- 21.50
- EPS (trailing)
- $-4.63
- Dividend yield
- —
- Beta
- 0.68
- Avg. volume
- 964.9K
How Vanda Pharmaceuticals Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 12, 2026 · via SEC EDGAR / Finnhub
Forecasts
5 analyst ratings
Vanda Pharmaceuticals Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- VNDAVanda Pharmaceuticals Inc. Common Stock$4.03▼ 4.95%Market cap $307.59MP/E —$4.27$9.94
- IRDOpus Genetics Inc. Common Stock$3.84▼ 5.19%Market cap $307.14MP/E —$1.7$7.07
- ORGOOrganogenesis Holdings Inc. Class A Common Stock$1▼ 9.91%Market cap $310.11MP/E 84.95$1.13$7.08
- AMRNAmarin Corporation plc$11.32▼ 2.16%Market cap $301.21MP/E —$11.34$20.9
- GALTGalectin Therapeutics Inc. Common Stock$3.62▼ 2.43%Market cap $324.74MP/E —$2.03$7.13
- IMRXImmuneering Corporation Class A Common Stock$3.59▼ 1.37%Market cap $288.55MP/E —$3.6$8.48
- FHTXFoghorn Therapeutics Inc. Common Stock$1.85▼ 2.12%Market cap $327.04MP/E —$1.79$7.61
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| VNDA Vanda Pharmaceuticals Inc. Common Stock | $307.59M | — | $4.03 | ▼ 4.95% | $4.27$9.94 |
| IRD Opus Genetics Inc. Common Stock | $307.14M | — | $3.84 | ▼ 5.19% | $1.7$7.07 |
| ORGO Organogenesis Holdings Inc. Class A Common Stock | $310.11M | 84.95 | $1 | ▼ 9.91% | $1.13$7.08 |
| AMRN Amarin Corporation plc | $301.21M | — | $11.32 | ▼ 2.16% | $11.34$20.9 |
| GALT Galectin Therapeutics Inc. Common Stock | $324.74M | — | $3.62 | ▼ 2.43% | $2.03$7.13 |
| IMRX Immuneering Corporation Class A Common Stock | $288.55M | — | $3.59 | ▼ 1.37% | $3.6$8.48 |
| FHTX Foghorn Therapeutics Inc. Common Stock | $327.04M | — | $1.85 | ▼ 2.12% | $1.79$7.61 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- HC Wainwright & Co. Reiterates Buy on Vanda Pharmaceuticals, Maintains $20 Price TargetBenzinga · 10/5/2026
- Vanda Pharmaceuticals Announces Presentation at 2026 EADV Annual MeetingYahoo · 10/2/2026
- Vanda: 'Hold' On Hetlioz Trial Win, But Several Risk Factors Remain For ItSeekingAlpha · 10/1/2026
- VNDA Stock Fades After Hetlioz Sleep-Trial Win — Here’s WhyYahoo · 9/30/2026
- Vanda Eyes First FDA-Approved Delayed Sleep-Wake Disorder DrugBenzinga · 9/30/2026
- Biotech Lagged The Broader Market In September — Did Retail Favorites SLS, IBRX, VNDA And IOVA Dodge XBI’s Slump?Yahoo · 9/30/2026
- Vanda Pharmaceuticals Announces Positive Phase III Results for HETLIOZ®(tasimelteon) in Delayed Sleep-Wake Phase DisorderYahoo · 9/29/2026
- Oppenheimer Initiates Coverage On Vanda Pharmaceuticals with Outperform Rating, Announces Price Target of $10Benzinga · 9/23/2026
Insider Activity
Insider Actions →- Richard W. Dugan · June 4, 2026 · Grant41.6K
- Daniel Patrick McGuire · June 4, 2026 · Grant80.0K
- Phaedra Chrousos · June 4, 2026 · Grant41.6K
- Charles Cliff Duncan · June 4, 2026 · Grant41.6K
- Anne Sempowski Ward · June 4, 2026 · Grant41.6K
- Tage Honore · June 4, 2026 · Grant41.6K
- Stephen Ray Mitchell · June 4, 2026 · Grant41.6K
- Stephen Ray Mitchell · May 18, 2026 · Gift25.8K
- Charles Cliff Duncan · April 22, 2026 · Grant57.1K
Institutional Ownership
March 31, 2026
- Total shares held
- 44.94M
- Total value held
- $286.71M
- Institutional holders
- 164
- Unknown7.28M
- Unknown3.76M
- Unknown3.02M
- Unknown2.75M
- Unknown2.48M
- Unknown1.88M
- Unknown1.80M
- Unknown1.77M
- Unknown1.60M
- Unknown1.44M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
Oppenheimer Launches Coverage on Vanda Pharmaceuticals
Oppenheimer has begun covering Vanda Pharmaceuticals, issuing an outperform rating and a $10 price target. The target sits near the middle of the analyst range and below the 52‑week high, suggesting a cautious upside view. The stock is trading above its $5.21 support level with an RSI of 41.6, indicating room for movement.
Oppenheimer Launches Coverage on Vanda Pharmaceuticals. Oppenheimer has begun covering Vanda Pharmaceuticals, issuing an outperform rating and a $10 price target. The target sits near the middle of the analyst range and below the 52‑week high, suggesting a cautious upside view. The stock is trading above its $5.21 support level with an RSI of 41.6, indicating room for movement.